Organogenesis (NASDAQ:ORGO) Issues Q4 Earnings Guidance

Organogenesis (NASDAQ:ORGO) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided EPS guidance of positive EPS for the period, compared to the Thomson Reuters consensus EPS estimate of $0.01. The company issued revenue guidance of $104.6-106.0 million, compared to the consensus revenue estimate of $80.84 million.Organogenesis also updated its FY 2020
After-Hours guidance to EPS.

Shares of Organogenesis stock traded up $2.76 during trading hours on Thursday, reaching $10.10. The company had a trading volume of 29,270 shares, compared to its average volume of 609,483. The business has a fifty day simple moving average of $6.18 and a 200 day simple moving average of $4.56. Organogenesis has a one year low of $2.47 and a one year high of $8.05. The company has a debt-to-equity ratio of 2.95, a current ratio of 1.78 and a quick ratio of 1.35. The firm has a market cap of $1.09 billion, a PE ratio of -27.30 and a beta of 1.33.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.27. Organogenesis had a negative return on equity of 101.41% and a negative net margin of 13.58%. The firm had revenue of $100.80 million during the quarter, compared to analyst estimates of $99.50 million. On average, research analysts forecast that Organogenesis will post -0.36 EPS for the current year.

Several equities analysts have recently weighed in on ORGO shares. TheStreet upgraded Organogenesis from a d rating to a c rating in a report on Wednesday, December 2nd. BidaskClub raised Organogenesis from a buy rating to a strong-buy rating in a research report on Saturday, January 9th. Oppenheimer reaffirmed a buy rating and set a $9.00 price objective on shares of Organogenesis in a research report on Monday, September 21st. BTIG Research restated a buy rating and set a $10.00 target price on shares of Organogenesis in a research report on Wednesday, October 14th. Finally, ValuEngine lowered shares of Organogenesis from a buy rating to a hold rating in a research report on Monday, November 23rd. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Organogenesis has a consensus rating of Buy and a consensus price target of $8.50.

In other news, Director Wayne D. Mackie purchased 38,710 shares of Organogenesis stock in a transaction dated Wednesday, December 2nd. The shares were purchased at an average price of $5.26 per share, with a total value of $203,614.60. Following the transaction, the director now owns 200,000 shares in the company, valued at $1,052,000. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Michael W. Katz bought 20,829 shares of the business’s stock in a transaction on Tuesday, November 17th. The stock was purchased at an average cost of $3.25 per share, for a total transaction of $67,694.25. Following the transaction, the insider now owns 34,432 shares of the company’s stock, valued at $111,904. The disclosure for this purchase can be found here. Insiders acquired a total of 138,492 shares of company stock worth $590,220 over the last three months. Corporate insiders own 70.40% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Further Reading: Special Dividends